ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
Company is on track with ongoing repeat-dose study under allergen-induced allergic rhinitis conditions requested by U.S. FDA with topline data expected in Q1 2024
Related news for (SPRY)
- ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
- ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
- ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
- 24/7 Market News Snapshot 20 March, 2025 – ARS Pharmaceuticals, Inc. Common Stock (NASDAQ:SPRY)
- MoBot alert highlights: NASDAQ: PSTV, NASDAQ: AEVA, NASDAQ: TDTH, NASDAQ: SPRY, NASDAQ: ADTX (03/20/25 09:00 AM)